(Press-News.org) COLUMBUS, Ohio – Two clinical studies published in the New England Journal of Medicine with an accompanying editorial suggest that the novel agent ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chronic lymphocytic leukemia (CLL) and for patients with mantle cell lymphoma (MCL).
Both studies, co-led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and at MD Anderson Cancer Center, were published in the Journal's June 19, 2013 online edition.
Chronic Lymphocytic Leukemia and Ibrutinib
Results from the phase Ib/II trial showed an overall response rate (complete and partial) of 71 percent. At 26 months the estimated progression-free survival rate was 75 percent and overall survival was 83 percent.
"Essentially all CLL patients respond well to ibrutinib, which lacks many of the side effects of chemotherapy and frequently produces long-lasting remissions even in patients with high-risk genetic lesions," says study co-leader John C. Byrd, MD, director of the division of hematology and a CLL specialist at the OSUCCC – James.
CLL is the most common form of leukemia with an estimated 15,000 American diagnosed annually. It is a cancer of B cells, which are a major component of the immune system along with T cells. Ibrutinib (PCI-32765) is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation. Ibrutinib kills malignant B cells but has little effect on healthy T cells – unlike other CLL therapies. This leaves an important arm of the immune system largely intact, enabling patients to remain healthier during treatment.
The trial involved 85 relapsed CLL patients (median age, 66) who took ibrutinib once daily. Fifty-one patients received a 420 mg dose and 34 patients received an 840 mg dose. Long-term therapy was associated with modest side effects such as diarrhea, fatigue, and infection that usually resolved with no treatment delay.
Funding for the study was provided by Pharmacyclics, Inc.; the Leukemia and Lymphoma Society; D. Warren Brown Foundation; Mr. and Mrs. Michael Thomas; the Harry Mangurian Foundation; and the NIH/National Cancer Institute (grant CA140158 and CA095426).
Mantle Cell Lymphoma and Ibrutinib
Results from this phase II trial showed an overall response rate of 68 percent, with 21 percent of patient achieving a complete response and 47 percent achieving a partial response. Estimated overall survival was 58 percent at 18 months.
"This is remarkable because the last agent approved by the Food and Drug Administration for MCL had a 30 percent response rate," says senior author Kristie Blum, MD, associate professor of medicine, and head of the OSUCCC – James lymphoma program. "This trial suggests that ibrutinib could significantly improve the landscape of therapy options for MCL."
VIDEO:
This video discusses a drug that shows surprising efficacy as treatment for chronic leukemia.
Click here for more information.
MCL is a type of non-Hodgkin lymphoma, a malignancy that is expected to strike nearly 70,000 Americans in 2013. About 7 percent of those cases will be MCL, a cancer of white blood cells called B lymphocytes, or B cells. Currently, oncologists treat MCL using combination chemotherapy or intensive chemotherapy plus immunotherapy, followed by stem-cell transplantation.
The trial involved 111 patients with relapsed or refractory MCL who took ibrutinib. The trial was conducted at 18 sites. Participants had received one to five prior treatments, which could include the drug bortezomib, an agent sometimes used to treat MCL. The estimated median response duration was 17.5 months and estimated median progression-free survival was 14 months.
INFORMATION:
Funding for the study was provided by Pharmacyclics, Inc.
About OSUCCC-James
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 228-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report.
Clinical results published online in NEJM show ibrutinib significantly prolongs survival in all classes of chronic lymphocytic leukemia (CLL) patients, even those at high-risk of recurrence; Similar results were shown in patients with mantle-cell lymphoma (MCL);
Ibrutinib is the first drug designed to target Bruton's tyrosine kinase, a protein critical in the B-cell receptor pathway for tumor cell survival and growth;
CLL, the most common form of leukemia, and MCL, a rare, aggressive form of non-Hodgkin lymphoma, are both incurable.
In CLL, the rate of overall survival at 26 months was an estimated 83 percent.
Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma
2013-06-20
ELSE PRESS RELEASES FROM THIS DATE:
World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu
2013-06-20
WASHINGTON, Wednesday June 19, 2013 - The Flemish plant scientist Marc Van Montagu (born 1933) is being awarded the "World Food Prize 2013", jointly with the American scientists Mary-Dell Chilton and Robert T. Fraley. This was announced in Washington DC on Wednesday by the US Secretary of State, John Kerry. The World Food Prize - the "Nobel Prize for food and agriculture" - gives the award annually to one or more people whose work has been of exceptional social importance for the quality, quantity or availability of food. This is the first time that a Belgian has won this ...
Hartford consensus aims to improve survival after mass shootings
2013-06-20
Philadelphia, PA (June 19, 2013) – In early April, senior leaders from medical, law enforcement, military, and fire/rescue agencies met in Hartford, Connecticut, to discuss one question: how can first responders improve survival after a mass casualty event?
The preliminary results of this discussion are now available in "Improving Survival from Active Shooter Events: The Hartford Consensus," a concept paper published in the June issue of the Journal of Trauma and Acute Care Surgery, official publication of the American Association for the Surgery of Trauma. The journal ...
Why are some college students more likely to 'hook up'?
2013-06-20
(PROVIDENCE, R.I.) – Casual, no-strings sexual encounters are increasingly common on college campuses, but are some students more likely than others to "hook up"? A new study by researchers with The Miriam Hospital's Centers for Behavioral and Preventive Medicine, published online by the Archives of Sexual Behavior, suggests there are certain factors and behaviors associated with sexual hookups, particularly among first-year college women.
"Given the potential for negative emotional and physical health outcomes as a result of sexual hookups, including unplanned pregnancy ...
Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds
2013-06-20
ROCHESTER, Minn. -- Nearly 70 percent of Americans are on at least one prescription drug, and more than half take two, Mayo Clinic researchers say. Antibiotics, antidepressants and painkilling opioids are most commonly prescribed, their study found. Twenty percent of patients are on five or more prescription medications, according to the findings, published online in the journal Mayo Clinic Proceedings.
MULTIMEDIA ALERT: For audio and video of Dr. Jennifer St. Sauver talking about the study, visit the Mayo Clinic News Network. (http://newsnetwork.mayoclinic.org/)
Researchers ...
Sequentially expressed genes in neural progenitors create neural diversity, NYU biologists find
2013-06-20
A team of New York University biologists has found that a series of genes sequentially expressed in brain stem cells control the generation of neural diversity in visual system of fruit flies. Their results are reported in the latest issue of the journal Nature.
In order for the brain to properly develop and function, a vast array of different types of neurons and glia must be generated from a small number of progenitor cells. By better understanding the details of this process, scientists can develop ways to recognize and remedy a range of neural afflictions such as ...
Expressly unfit for the laboratory
2013-06-20
A new study challenges the orthodoxy of microbiology that in response to environmental changes, bacterial genes will boost production of needed proteins and decrease production of those that aren't. Researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) found that for bacteria in the laboratory there was little evidence of adaptive genetic response. In fact, most bacterial genes appear to be regulated by signals unrelated to their function.
"Gene regulation in bacteria is usually described as an adaptive response to ...
Scientists date prehistoric bacterial invasion still present in today's cells
2013-06-20
Long before plants and animals inhabited the earth, when life consisted of single-celled organisms afloat in a planet-wide sea, bacteria invaded these organisms and took up permanent residence. One bacterium eventually became the mitochondria that today power all plant and animal cells; another became the chloroplast that turns sunlight into energy in green plants.
A new analysis by two University of California, Berkeley, graduate students more precisely pinpoints when these life-changing invasions occurred, placing the origin of photosynthesis in plants hundreds of millions ...
Genetics of cervical cancer raise concern about antiviral therapy in some cases
2013-06-20
CORVALLIS, Ore. – A new understanding of the genetic process that can lead to cervical cancer may help improve diagnosis of potentially dangerous lesions for some women, and also raises a warning flag about the use of anti-viral therapies in certain cases – suggesting they could actually trigger the cancer they are trying to cure.
The analysis provides a clearer picture of the chromosomal and genetic changes that take place as the human papillomavirus sometimes leads to chronic infection and, in less than 1 percent of cases, to cervical cancer. It is the first to identify ...
Metamorphosis of moon's water ice explained
2013-06-20
DURHAM, N.H. –- Using data gathered by NASA's Lunar Reconnaissance Orbiter (LRO) mission, scientists believe they have solved a mystery from one of the solar system's coldest regions—a permanently shadowed crater on the moon. They have explained how energetic particles penetrating lunar soil can create molecular hydrogen from water ice. The finding provides insight into how radiation can change the chemistry of water ice throughout the solar system.
Space scientists from the University of New Hampshire and NASA's Goddard Space Flight Center have published their results ...
UMass Amherst researchers develop powerful new technique to study protein function
2013-06-20
AMHERST, Mass. – In the cover story for the journal Genetics this month, neurobiologist Dan Chase and colleagues at the University of Massachusetts Amherst describe a new experimental technique they developed that will allow scientists to study the function of individual proteins in individual cell types in a living organism.
The advance should allow deeper insights into protein function, Chase says, "because we can only get a true understanding of what that single protein does when we isolate its function in a living organism. There was no tool currently available to ...